Roberto Wandenkolk Vieira net worth and biography

Roberto Vieira Biography and Net Worth

President, Oncology of Corcept Therapeutics

Mr. Vieira joined Corcept as President of Oncology in January 2024. He brings more than 20 years of sales, marketing, and oncology experience to his role. Mr. Vieira previously served as Senior Vice President of U.S. Commercial at Mirati Therapeutics, Inc., where he built the U.S. commercial organization and led the launch of the company’s first targeted cancer therapy for the treatment of advanced non-small cell lung cancer. Prior to that, Mr. Vieira spent 15 years at Bristol-Myers Squibb in positions of increasing seniority, including Vice President of Worldwide Oncology Strategy. He also served as General Manager in Europe (The Netherlands) and was part of the leadership team that led the introduction of transformational medicines in the Immuno-Oncology space across a broad range of solid tumors. Prior to Bristol-Myers Squibb, Mr. Vieira spent 10 years at Eli Lilly and Company where he worked across manufacturing, finance, sales and marketing.

Mr. Vieira holds an MBA in Business Administration and Management from the University of Pittsburgh. He also holds a diploma in Chemical Engineering from Universidade Estadual de Campinas (UNICAMP) in São Paulo, Brazil and has completed the General Management Program at CEDEP, France.

What is Roberto Wandenkolk Vieira's net worth?: The estimated net worth of Roberto Wandenkolk Vieira is at least $473.49 thousand as of September 2nd, 2026. Mr. Vieira owns 4,242 shares of Corcept Therapeutics stock worth more than $473,492 as of September 8th. This net worth approximation does not reflect any other assets that Mr. Vieira may own. Learn More about Roberto Wandenkolk Vieira's net worth.
How do I contact Roberto Wandenkolk Vieira?: The corporate mailing address for Mr. Vieira and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Roberto Wandenkolk Vieira's contact information.
Has Roberto Wandenkolk Vieira been buying or selling shares of Corcept Therapeutics?: During the past quarter, Roberto Wandenkolk Vieira has sold $6,460,963.08 of Corcept Therapeutics stock. Most recently, Roberto Wandenkolk Vieira sold 58,333 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $110.76, for a transaction totalling $6,460,963.08. Following the completion of the sale, the insider now directly owns 4,242 shares of the company's stock, valued at $469,843.92. Learn More on Roberto Wandenkolk Vieira's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Atabak Mokari (CFO), Kimberly Park (Director), Gary Robb (CFO), Daniel Swisher, Jr. (Director), Roberto Vieira (President, Oncology), and James Wilson (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, Corcept Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $3,314,000.00. In the last year, insiders at the biotechnology company sold shares 46 times. They sold a total of 1,051,217 shares worth more than $91,953,559.39. The most recent insider tranaction occured on September, 2nd when insider Roberto Wandenkolk Vieira sold 58,333 shares worth more than $6,460,963.08. Insiders at Corcept Therapeutics own 20.7% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 9/2/2026.

Roberto Wandenkolk Vieira Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/2/2026	Sell	58,333	$110.76	$6,460,963.08	4,242

Roberto Wandenkolk Vieira Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $113.07

$108.25

$112.77

50 Day Range

MA: $104.61

$85.90

$123.57

2 Week Range

Now: $113.07

$28.66

$126.38

Volume

106,825 shs

Average Volume

1,487,352 shs

Market Capitalization

$12.22 billion

P/E Ratio

269.11

Dividend Yield

N/A

Beta

0.45